Pramukti Hikmat, Yunihastuti Evy, Gani Rino A, Rinaldi Ikhwan, Hasan Irsan, Maria Suzy
Faculty of Medicine, Department of Internal Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
SAGE Open Med. 2024 Dec 18;12:20503121241292678. doi: 10.1177/20503121241292678. eCollection 2024.
BACKGROUND/OBJECTIVES: As people with human immunodeficiency virus experience longer life expectancy, other causes of morbidity and mortality are being increasingly identified. The incidence of non-alcoholic fatty liver disease has recently been on the rise in Indonesia. People with human immunodeficiency virus on antiretroviral therapy are also at an increased risk of having non-alcoholic fatty liver disease. The study aimed to define the prevalence and factors associated with non-alcoholic fatty liver disease in people with human immunodeficiency virus on stable antiretroviral therapy.
A cross-sectional study of people with human immunodeficiency virus, on antiretroviral therapy, age younger than 18 years old, and without hepatitis co-infection was conducted at the human immunodeficiency virus Integrated Clinic Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Non-alcoholic fatty liver disease was diagnosed using transient elastography with associated controlled attenuation parameter examination (diagnostic cutoff: 238 db/m). A logistic regression test with Poisson regression was used to evaluate factors associated with non-alcoholic fatty liver disease.
One hundred and five people with human immunodeficiency virus were included, with a median age of 39 years and 65.7% were men. The prevalence of non-alcoholic fatty liver disease was 52.4%. Factors related to non-alcoholic fatty liver disease were hypertension (aPR: 1.49, 95% CI: 1.03-2.14, = 0.033) and triglyceride levels (aPR: 1.001, 95% CI: 1.000-1.002, = 0.024). No human immunodeficiency virus-specific variables were associated with non-alcoholic fatty liver disease.
More than half of Indonesian people with human immunodeficiency virus on antiretroviral therapy in this study were found to have non-alcoholic fatty liver disease. Hypertension and increased triglyceride levels were related to non-alcoholic fatty liver disease. Screening for non-alcoholic fatty liver disease should be implemented as a means of early intervention and to prevent complications.
背景/目的：随着人类免疫缺陷病毒感染者的预期寿命延长，其他发病和死亡原因日益得到确认。印度尼西亚非酒精性脂肪性肝病的发病率最近呈上升趋势。接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者患非酒精性脂肪性肝病的风险也有所增加。本研究旨在确定接受稳定抗逆转录病毒治疗的人类免疫缺陷病毒感染者中非酒精性脂肪性肝病的患病率及相关因素。
在印度尼西亚雅加达的Cipto Mangunkusumo医院人类免疫缺陷病毒综合诊所，对年龄小于18岁、未合并肝炎感染且接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者进行了一项横断面研究。使用瞬时弹性成像结合受控衰减参数检查诊断非酒精性脂肪性肝病（诊断临界值：238 db/m）。采用泊松回归的逻辑回归检验评估与非酒精性脂肪性肝病相关的因素。
纳入了105名人类免疫缺陷病毒感染者，中位年龄为39岁，65.7%为男性。非酒精性脂肪性肝病的患病率为52.4%。与非酒精性脂肪性肝病相关的因素为高血压（调整后风险比：1.49，95%置信区间：1.03 - 2.14，P = 0.033）和甘油三酯水平（调整后风险比：1.001，95%置信区间：1.000 - 1.002，P = 0.024）。没有人类免疫缺陷病毒特异性变量与非酒精性脂肪性肝病相关。
本研究发现，在印度尼西亚接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者中，超过一半患有非酒精性脂肪性肝病。高血压和甘油三酯水平升高与非酒精性脂肪性肝病相关。应实施非酒精性脂肪性肝病筛查，作为早期干预和预防并发症的手段。
